Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial. Kytola S, Vanttinen IM, Ruokoranta T, Partanen A, et al. Blood 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.

Read + Share

Amedeo Smart

Independent Medical Education

Kytola S, Vanttinen IM, Ruokoranta T, Partanen A, et al. Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial. Blood 2024 Oct 2:blood.2024024968. doi: 10.1182/blood.2024024968.
PMID: 39357056